Beta
ManageChatDiscover
414824

Effects of sarilumab on IL-6, IL-10 and IP-10 levels in critically ill COVID-19 patients

Article

Last updated: 09 Mar 2025

OverviewSimilar Items

Subjects

-

Tags

Clinical microbiology

Abstract

Background: Pandemic COVID-19 caused by SARS-CoV-2. The infection is associated with an inflammatory cytokine storm, which is characterized by elevated levels of pro-inflammatory cytokines as IL-6 and IP-10. Some non-inflammatory cytokines have been investigated in COVID-19 critical cases as IL-10. Early blockade of IL6-pathway might be beneficial in decreasing disease severity. The prospect of employing tocilizumab and sarilumab to treat or prevent the cytokine storm has generated a lot of interest recently. Objective: A trial to evaluate effects of sarilumab on IL-6, IL-10, IP-10 in critically ill COVID-19 patients was done in this study. Methodology: Thirty critically ill COVID-19 patients were enrolled in this study and received sarilumab. Serum baseline, 24hrs and 72hrs after treatment levels of IL-6, IL-10 and IP-10 were evaluated by ELISA kits. Results: Serum levels of IL-6, PaO2 and P/F ratio increased significantly 24hrs after treatment, while levels of IL-10, IP-10 decreased significantly after treatment. There was positive correlation between some markers at baseline level, 24hrs after treatment and 72hrs after treatment, suggesting that these markers are affected by treatment with sarilumab. Accuracy of IL-6, IL-10 and IP-10 measurements 72 hrs after treatment with sarilumab shows significance, indicating that they can help in pathophysiology. Conclusion: COVID-19 infection is significantly associated with high CRP, D-dimer and accompanied with low levels of PaO2 and P/F ratio in critically ill cases. More than half of the ICU patients showed clinical amelioration after sarilumab administration. Dosing and timing of receiving sarilumab play a crucial role in the outcome.

DOI

10.21608/ejmm.2025.360033.1473

Keywords

COVID-19, IL-6, IL-10, IP-10, sarilumab

Authors

First Name

Reem

Last Name

Ahmed

MiddleName

M.

Affiliation

Directorate of Health and Population, Faculty of Pharmacy, Assiut University, Assiut, Egypt.

Email

reemelbadawy93@gmail.com

City

Assiut

Orcid

-

First Name

Khaled

Last Name

Hasanein

MiddleName

M.

Affiliation

Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Egypt

Email

khaledhassanein70@aun.edu.eg

City

Assiut

Orcid

-

First Name

Mohamed

Last Name

El-Mokhtar

MiddleName

A.

Affiliation

Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Egypt

Email

elmokhtarma@aun.edu.eg

City

Assuit

Orcid

-

First Name

Mohammad

Last Name

Khalaf

MiddleName

G.A.

Affiliation

Department of Chest Diseases, Assiut University Hospital, Assiut University, Assiut, Egypt

Email

dr.mga2011@aun.edu.eg

City

Assiut

Orcid

-

First Name

Aliaa

Last Name

Ghandour

MiddleName

M.A.

Affiliation

Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Egypt

Email

aliaaghandour@yahoo.com

City

Assiut

Orcid

-

Volume

34

Article Issue

3

Related Issue

53640

Issue Date

2025-07-01

Receive Date

2025-02-12

Publish Date

2025-07-01

Print ISSN

1110-2179

Online ISSN

2537-0979

Link

https://ejmm.journals.ekb.eg/article_414824.html

Detail API

http://journals.ekb.eg?_action=service&article_code=414824

Order

414,824

Type

New and original researches in the field of Microbiology.

Type Code

2,038

Publication Type

Journal

Publication Title

Egyptian Journal of Medical Microbiology

Publication Link

https://ejmm.journals.ekb.eg/

MainTitle

Effects of sarilumab on IL-6, IL-10 and IP-10 levels in critically ill COVID-19 patients

Details

Type

Article

Created At

09 Mar 2025